representative work

Theralase Completes $17.25 Million Prospectus Offering


On August 22, 2019, Theralase Technologies Inc. completed a short form prospectus offering pursuant to which 57,500,000 units of Theralase were issued (including the exercise in full of the over-allotment option) at a price of $0.30 per unit for gross proceeds of $17.25 million. Each unit consisted of one common share and one common share purchase warrant of Theralase. Each warrant shall be exercisable to acquire one common share at a price of $0.35 until August 22, 2024.

Cassels acted for Theralase with a deal team that included Andrea FitzGerald, Nancy Choi, and Jasmine Qin (Securities) and Chris Norton (Tax).

RELATED EXPERTISE: Securities | Taxation